Perceptive Advisors LLC Acquires New Stake in PRA Health Sciences, Inc. (PRAH)

Perceptive Advisors LLC bought a new position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,427 shares of the medical research company’s stock, valued at approximately $566,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Renaissance Group LLC boosted its holdings in PRA Health Sciences by 2.5% during the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after purchasing an additional 126 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in PRA Health Sciences by 1.9% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after purchasing an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after purchasing an additional 160 shares during the last quarter. Zacks Investment Management boosted its holdings in PRA Health Sciences by 1.3% during the second quarter. Zacks Investment Management now owns 48,885 shares of the medical research company’s stock worth $3,667,000 after purchasing an additional 614 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in PRA Health Sciences by 4.9% in the second quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock valued at $1,100,000 after acquiring an additional 690 shares during the last quarter. Institutional investors and hedge funds own 98.49% of the company’s stock.

In other news, Director Matthew P. Young sold 5,115 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is owned by corporate insiders.

A number of brokerages have commented on PRAH. Raymond James Financial began coverage on shares of PRA Health Sciences in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $89.00 price target for the company. Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research note on Tuesday, August 15th. SunTrust Banks reiterated a “buy” rating and issued a $101.00 price target on shares of PRA Health Sciences in a research note on Friday, October 27th. Mizuho began coverage on shares of PRA Health Sciences in a research note on Thursday, September 21st. They issued a “buy” rating and a $82.00 price target for the company. Finally, Credit Suisse Group increased their price target on shares of PRA Health Sciences from $90.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $89.09.

PRA Health Sciences, Inc. (NASDAQ PRAH) opened at $82.71 on Monday. The firm has a market cap of $5,241.31, a PE ratio of 30.41, a PEG ratio of 1.43 and a beta of 0.40. PRA Health Sciences, Inc. has a 1 year low of $53.47 and a 1 year high of $84.38. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 earnings per share. sell-side analysts predict that PRA Health Sciences, Inc. will post 3.2 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://weekherald.com/2017/12/11/perceptive-advisors-llc-acquires-new-stake-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply